Logo image of BMA.OL

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

Europe - OSL:BMA - NO0003087603 - Common Stock

15.5 NOK
+0.2 (+1.31%)
Last: 10/6/2025, 7:00:00 PM
Fundamental Rating

1

BMA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 23 industry peers in the Building Products industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BMA has reported negative net income.
BMA had a positive operating cash flow in the past year.
BMA had positive earnings in 4 of the past 5 years.
In the past 5 years BMA always reported a positive cash flow from operatings.
BMA.OL Yearly Net Income VS EBIT VS OCF VS FCFBMA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

The Return On Assets of BMA (-1.97%) is worse than 82.61% of its industry peers.
BMA's Return On Equity of -6.12% is on the low side compared to the rest of the industry. BMA is outperformed by 78.26% of its industry peers.
BMA has a worse Return On Invested Capital (2.25%) than 78.26% of its industry peers.
Industry RankSector Rank
ROA -1.97%
ROE -6.12%
ROIC 2.25%
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)N/A
ROIC(5y)N/A
BMA.OL Yearly ROA, ROE, ROICBMA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

BMA's Operating Margin of 2.90% is on the low side compared to the rest of the industry. BMA is outperformed by 78.26% of its industry peers.
The Gross Margin of BMA (50.09%) is better than 69.57% of its industry peers.
BMA's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.9%
PM (TTM) N/A
GM 50.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
BMA.OL Yearly Profit, Operating, Gross MarginsBMA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

0

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMA is destroying value.
BMA has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BMA has more shares outstanding
The debt/assets ratio for BMA is higher compared to a year ago.
BMA.OL Yearly Shares OutstandingBMA.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BMA.OL Yearly Total Debt VS Total AssetsBMA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.46, we must say that BMA is in the distress zone and has some risk of bankruptcy.
BMA has a Altman-Z score of 1.46. This is in the lower half of the industry: BMA underperforms 69.57% of its industry peers.
BMA has a Debt/Equity ratio of 1.19. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.19, BMA is doing worse than 78.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.19
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACC0.25
WACC8.92%
BMA.OL Yearly LT Debt VS Equity VS FCFBMA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 0.78 indicates that BMA may have some problems paying its short term obligations.
With a Current ratio value of 0.78, BMA is not doing good in the industry: 86.96% of the companies in the same industry are doing better.
A Quick Ratio of 0.44 indicates that BMA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.44, BMA is doing worse than 82.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.44
BMA.OL Yearly Current Assets VS Current LiabilitesBMA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

BMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.50%, which is quite impressive.
BMA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.30%.
Measured over the past years, BMA shows a small growth in Revenue. The Revenue has been growing by 3.98% on average per year.
EPS 1Y (TTM)29.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%191.48%
Revenue 1Y (TTM)6.3%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%17.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMA.OL Yearly Revenue VS EstimatesBMA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMA.OL Price Earnings VS Forward Price EarningsBMA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

69.57% of the companies in the same industry are cheaper than BMA, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.25
BMA.OL Per share dataBMA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BYGGMA ASA

OSL:BMA (10/6/2025, 7:00:00 PM)

15.5

+0.2 (+1.31%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.71%
Ins Owner ChangeN/A
Market Cap1.08B
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF 20.88
P/B 1.1
P/tB 1.12
EV/EBITDA 14.25
EPS(TTM)-0.84
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.74
OCFY4.79%
SpS32.39
BVpS14.04
TBVpS13.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.97%
ROE -6.12%
ROCE 3.37%
ROIC 2.25%
ROICexc 2.28%
ROICexgc 2.3%
OM 2.9%
PM (TTM) N/A
GM 50.09%
FCFM N/A
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
F-Score6
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 1.19
Debt/FCF N/A
Debt/EBITDA 7.61
Cap/Depr 60.63%
Cap/Sales 2.35%
Interest Coverage 0.62
Cash Conversion 33.77%
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.44
Altman-Z 1.46
F-Score6
WACC8.92%
ROIC/WACC0.25
Cap/Depr(3y)82.97%
Cap/Depr(5y)85.75%
Cap/Sales(3y)3.16%
Cap/Sales(5y)3.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%191.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.3%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%17.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y142.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-101.01%
FCF growth 3Y-35.16%
FCF growth 5YN/A
OCF growth 1Y-80.63%
OCF growth 3Y-28.69%
OCF growth 5Y-8.56%